Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells
Immune Network
;
: 58-65, 2015.
Artigo
em Inglês
| WPRIM
| ID: wpr-70039
ABSTRACT
Melanoma is the most aggressive skin cancer and its incidence is gradually increasing worldwide. Patients with metastatic melanoma have a very poor prognosis (estimated 5-year survival rate of <16%). In the last few years, several drugs have been approved for malignant melanoma, such as tyrosine kinase inhibitors and immune checkpoint blockades. Although new therapeutic agents have improved progression-free and overall survival, their use is limited by drug resistance and drug-related toxicity. At the same time, adoptive cell therapy of metastatic melanoma with tumor-infiltrating lymphocytes has shown promising results in preclinical and clinical studies. In this review, we summarize the currently available drugs for treatment of malignant melanoma. In addition, we suggest cytokine-induced killer (CIK) cells as another candidate approach for adoptive cell therapy of melanoma. Our preclinical study and several previous studies have shown that CIK cells have potent anti-tumor activity against melanomas in vitro and in an in vivo human tumor xenograft model without any toxicity.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Prognóstico
/
Neoplasias Cutâneas
/
Proteínas Tirosina Quinases
/
Resistência a Medicamentos
/
Incidência
/
Taxa de Sobrevida
/
Linfócitos do Interstício Tumoral
/
Células Matadoras Induzidas por Citocinas
/
Xenoenxertos
/
Terapia Baseada em Transplante de Células e Tecidos
Tipo de estudo:
Estudo de incidência
/
Estudo prognóstico
Limite:
Humanos
Idioma:
Inglês
Revista:
Immune Network
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS